Mathematical Models Reveal How Shrinking Breast Tumors Move During Therapy
A study of 141 triple-negative breast cancer patients shows that advection terms in mathematical models best capture tumor cell movement ...
A study of 141 triple-negative breast cancer patients shows that advection terms in mathematical models best capture tumor cell movement ...
A case report describes advanced ovarian cancer shrinking dramatically after the PD-1 inhibitor sintilimab was added to chemotherapy, enabling complete ...
A phase II trial found that adjuvant sintilimab monotherapy after surgery met its primary efficacy endpoint with 87.5 percent one-year ...
A phase II trial found that neoadjuvant camrelizumab plus apatinib, a chemotherapy-free combination of immunotherapy and anti-angiogenic therapy, produced manageable ...
A new MD Anderson study finds that 57 percent of residual breast tumors lose HER2 overexpression after HER2-targeted neoadjuvant therapy, ...
A sweeping 2024–2025 evidence review shows immune checkpoint inhibitors, frailty-adapted surgery, and artificial intelligence converging to transform esophageal cancer treatment ...
A Phase III trial of 807 patients found the trastuzumab biosimilar EG12014 statistically equivalent to reference trastuzumab in efficacy, safety, ...
Researchers in China have built a predictive model combining preoperative MRI features and serum CA19-9 levels that accurately identifies pancreatic ...
A multicenter retrospective study of 154 patients finds that combining self-expandable metal stents with modern neoadjuvant therapy reduces stomas and ...
A retrospective cohort study of 215 patients finds that small node-negative triple-negative breast cancers show similar biology and outcomes across ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine